EUVIMEDEUVIMED entdecken
Crossref

Paeonol ameliorates diabetic nephropathy by promoting TFEB-mediated lysosome biogenesis and lipophagy

Sinan Ai, Jiayin Tao, Yaoxian Wang, Jingwei Zhou, Weijing Liu, Xi Li, Lin Wang, Jinyi Hou, Leying Zhao, Zhen Wang, Liang Peng

Phytomedicine · 2025-07 · 143 · 156901

DOI: 10.1016/j.phymed.2025.156901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025-07. Verfasst von Sinan Ai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China; Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases,…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Acetophenones, Autophagy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Beijing University of Chinese Medicine, Natural Science Foundation of Beijing Municipality, Innovative Research Group Project of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE: Diabetic nephropathy (DN) is a significant clinical and public health burden worldwide whose magnitude underscores the urgent need for more effective treatment options. Excessive lipid accumulation in renal tubular cells leads to their injury and dysfunction, thereby contributing to DN progression, suggesting that the alleviation of renal tubular lipid accumulation is a potential strategy for treating DN. METHODS: The effects of paeonol (PAE), a natural phenolic compound, on renal tubular lipid accumulation were evaluated using a glucolipotoxicity-treated HK-2 cell line and C57BL/6 J mice treated with streptozotocin (STZ) injection combined with a high-fat diet (HFD). Autophagic flux and lipophagy were assessed through immunofluorescence, adenoviral mRFP-GFP-LC3 transfection, and western blotting. Small interfering RNA (siRNA) was used for in vitro experiments to silence Tfeb in HK-2 cells, while a Cre-loxP system was employed to induce Tfeb knockout specifically in renal tubules in vivo, to validate the therapeutic target of PAE. RNA sequencing, pulldown assays, surface plasmon resonance (SPR), and molecular docking were utilized to further explore the specific molecular mechanisms involved. RESULTS: We found that PAE dose-dependently alleviated renal tubular lipid accumulation in glucolipotoxicity-treated HK-2 cells and the DN mouse model. Mechanistically, PAE directly binds to RHEB, functioning as an mTOR suppressor, thereby activating TFEB to promote lysosome biogenesis and lipophagy, subsequently alleviating renal tubular lipid accumulation and DN progression. CONCLUSIONS: Per our findings, PAE holds promise as a therapeutic agent for DN, with the unique mechanism of activating renal TFEB-mediated lipophagy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsAcetophenonesAutophagyLysosomesAnimalsMice, Inbred C57BLHumansMiceMaleCell LineDiabetes Mellitus, ExperimentalLipid MetabolismDiet, High-FatKidney TubulesMolecular Docking Simulation

Stichwörter der Autor:innen

Diabetic nephropathyLipophagyPaeonolRenal lipid accumulationTFEB

Substanzen

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsAcetophenonespaeonolTcfeb protein, mouseTFEB protein, human

Autor:innen und Institutionen

  • Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China; Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospit…
  • Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China; Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Me…
  • Henan University of Chinese Medicine, Henan 450046, China.
  • Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, No 2 Yinghua East Street, Chaoyang District, Beijing 100029, China.
  • Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100029, China.
  • Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, No 2 Yinghua East Street, Chaoyang District, Beijing 100029, China. Electronic a…

Förderung

  • Beijing University of Chinese Medicine
  • Natural Science Foundation of Beijing Municipality
  • Innovative Research Group Project of the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Ai, S., Tao, J., Wang, Y., Zhou, J., Liu, W., Li, X., Wang, L., Hou, J., Zhao, L., Wang, Z., & Peng, L. (2025). Paeonol ameliorates diabetic nephropathy by promoting TFEB-mediated lysosome biogenesis and lipophagy. Phytomedicine, 143, 156901. https://doi.org/10.1016/j.phymed.2025.156901

Vancouver

Ai S, Tao J, Wang Y, Zhou J, Liu W, Li X, et al. Paeonol ameliorates diabetic nephropathy by promoting TFEB-mediated lysosome biogenesis and lipophagy. Phytomedicine. 2025;143:156901. doi:10.1016/j.phymed.2025.156901

BibTeX
@article{Ai2025,
  author = {Ai, Sinan and Tao, Jiayin and Wang, Yaoxian and Zhou, Jingwei and Liu, Weijing and Li, Xi and Wang, Lin and Hou, Jinyi and Zhao, Leying and Wang, Zhen and Peng, Liang},
  title = {Paeonol ameliorates diabetic nephropathy by promoting TFEB-mediated lysosome biogenesis and lipophagy},
  journal = {Phytomedicine},
  year = {2025},
  volume = {143},
  pages = {156901},
  doi = {10.1016/j.phymed.2025.156901}
}
Kostenlos starten →